CXCL10/Gamma Interferon-Inducible Protein 10-Mediated Protection againstLeishmania amazonensisInfection in Mice
- 1 December 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (12) , 6769-6777
- https://doi.org/10.1128/iai.01073-06
Abstract
Leishmania amazonensiscan cause progressive disease in most inbred strains of mice. We have previously shown thatL. amazonensis-infected C57BL/6 mice have profound impairments in expression of proinflammatory cytokines and chemokines and in activation of antigen-specific CD4+T cells. These impairments are independent of interleukin-4 (IL-4) but partially due to IL-10 production. The precise mechanism of pathogenesis associated withL. amazonensisinfection remains largely unresolved. Since chemokines are essential mediators of leukocyte recruitment and effector cell function, we hypothesized that these molecules are important for the initiation of early responses locally and for the eventual control of the infection. In this study, we examined the roles of CXCL10/gamma interferon-inducible protein 10 (IP-10) and CCL2/monocyte chemoattractant protein 1 (MCP-1) in the activation of the macrophage effector function in vitro and their efficacy in ameliorating infection in vivo. Bone marrow-derived macrophages of both BALB/c and C57BL/6 mice were treated with increasing concentrations of recombinant chemokines prior to infection with either stationary-phase promastigotes or tissue-derived amastigotes. We found that treatment with IP-10 or MCP-1 significantly reduced parasite burdens, in a dose-dependent manner, and triggered nitric oxide production. When susceptible C57BL/6 mice were injected locally with IP-10 followingL. amazonensisinfection, there was a significant delay in lesion development and a reduction in parasite burdens, accompanied by 7- and 3.5-fold increases in gamma interferon and IL-12 secretion, respectively, in restimulated lymph node cells. This study confirms that IP-10 plays a protective role in promoting the reduction of intracellular parasites and thereby opens new avenues for therapeutic control of nonhealing cutaneous leishmaniasis in the New World.Keywords
This publication has 45 references indexed in Scilit:
- CXCR3 is required for migration to dermal inflammation by normal andin vivo activated T cells: differential requirements by CD4 and CD8 memory subsetsEuropean Journal of Immunology, 2005
- Interleukin‐17: the missing link between T‐cell accumulation and effector cell actions in rheumatoid arthritis?Immunology & Cell Biology, 2004
- RecombinantLeishmania majorSecreting Biologically Active Granulocyte-Macrophage Colony-Stimulating Factor Survives Poorly in Macrophages In Vitro and Delays Disease Development in MiceInfection and Immunity, 2003
- Interleukin 1α Promotes Th1 Differentiation and Inhibits Disease Progression in Leishmania major–susceptible BALB/c MiceThe Journal of Experimental Medicine, 2003
- The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile CureThe Journal of Experimental Medicine, 2001
- Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-γ and is antagonized by IL-4European Journal of Immunology, 2000
- Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1Nature, 2000
- LEISHMANIA AMAZONENSISINFECTION DOES NOT INHIBIT SYSTEMIC NITRIC OXIDE LEVELS ELICITED BY LIPOPOLYSACCHARIDE IN VIVOJournal of Parasitology, 2000
- Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent mannerEuropean Journal of Immunology, 1999
- T-lymphocytes in experimentalLeishmania amazonensis infection: comparison between immunized and naive BALB/c miceZeitschrift Fur Parasitenkunde-Parasitology Research, 1992